Multi targeted antivirals {#cesec10}
=========================

HIV infection is often associated with infection with other sexually transmitted pathogens, particularly herpes simplex virus 2 (HSV-2). HSV-2 infections increase the risk of HIV acquisition and can worsen the clinical course of HIV disease. Thus, a [microbicide](http://dx.doi.org/10.1371/journal.ppat.1003456){#interrefs10} that is active against both viruses would be very useful. Researchers now report that PMEO-DAPym, which is structurally related to tenofovir and adefovir, efficiently inhibits HIV-1 reverse transcriptase and HSV-2 DNA polymerase. In addition, PMEO-DAPym induces the production of CC-chemokines and downregulates the HIV-1 co-receptor CCR5, and could, therefore, prevent the entry of HIV into its host cells.

Coronaviruses, bats, and camels {#cesec20}
===============================

A betacoronavirus called Middle East respiratory syndrome coronavirus ([MERS-CoV](http://dx.doi.org/10.3201/eid1910.130946){#interrefs20}) was recently identified as the causative agent of an emerging infectious disease that has killed 50 people in the Arabian Peninsula since 2012. But what are the animal reservoirs of this virus? An examination of faecal pellets collected from 13 species of bats in South Africa has identified a virus in *Neoromicia* cf *zuluensis* that is more closely genetically related to MERS-CoV than to any other known virus. In a separate study, researchers provide evidence that [camels](http://dx.doi.org/10.1016/S1473-3099(13)70164-6){#interrefs30} might also be a reservoir for MERS-CoV.

The daily commute contributes to disease networks© 2013 Ria Novosti/Science Photo Library2013Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company\'s public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Tuberculosis treatment {#cesec30}
======================

A screen of a chemical library followed by optimisation of the most promising lead compound has identified the imidazopyridine amide Q203 as a candidate for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) [tuberculosis](http://dx.doi.org/10.1038/nm.3262){#interrefs40}. Q203, which inhibits *Mycobacteria tuberculosis* growth by targeting its cellular energy production, limits the growth of MDR and XDR clinical isolates in vitro and is efficacious in a mouse model of tuberculosis at low doses. Moreover, the pharmacokinetic and safety profiles of Q203 are compatible with once-daily dosing.

Host reprogramming {#cesec40}
==================

Pathogens subvert [host](http://dx.doi.org/10.1126/science.1238858){#interrefs50} cell transcription programmes during infection to ensure their survival and replication but the mechanisms that underlie this subversion are unclear. A study now reports that, during infection with *Listeria monocytogenes*, the host histone deacetylase sirtuin 2 (SIRT2) moves into the nucleus, associates with the transcription start site of a subset of genes that is repressed during infection, and deacetylates histone H3 on lysine 18. Notably, bacterial infection is impaired in SIRT2^−/−^ mice. Together, these results identify an epigenetic mechanism that *L monocytogenes* uses to subvert DNA transcription in its host.

Brief encounters {#cesec50}
================

The spread of infectious diseases depends on [social](http://dx.doi.org/10.1073/pnas.1306440110){#interrefs60} networks but what drives daily encounters and the collective interactions of populations? A [study](http://dx.doi.org/10.1126/scitranslmed.3005893){#interrefs70} that used data from travel smart cards to uncover encounter patterns among bus users in Singapore suggests that an individual\'s encounters are bounded by collective regularities such as daily transportation peaks. Importantly, individuals with repeated encounters become connected over time into a city-wide but imperceptible social contact network. The identification of such networks is critical to understanding how human behaviour affects the spread of infectious diseases.

Death prediction in sepsis {#cesec60}
==========================

Sepsis mortality has decreased over the past decade but the prediction of outcomes in individual patients remains difficult. By examining the clinical features and the plasma metabolome and proteome of 1152 individuals with suspected community-acquired sepsis who were enrolled on arrival at US hospital emergency departments, researchers have derived an algorithm that predicts patient survival at the earliest stages of bloodstream infection. This model, which includes clinical features and measurement of five metabolites, could help to ensure that patients with sepsis receive the most appropriate treatment.

Drugs and fungal infection {#cesec70}
==========================

The use of [methamphetamine](http://dx.doi.org/10.1128/mBio.00400-13){#interrefs80}, an addictive central nervous system stimulant that also affects immunological responses, has been linked to HIV acquisition and might facilitate the progression of HIV infection. New research shows that methamphetamine enhances lung colonisation by *Cryptococcus neoformans*, the commonest cause of fungal meningitis in patients with AIDS, by stimulating fungal adhesion and biofilm formation and by altering the carbohydrate composition of the capsular polysaccharide (a fungal virulence factor). The research also shows that methamphetamine promotes fungal dissemination from the lungs into the brain.
